KLRK1 and myelodysplastic syndrome: An enhanced version of CYAD-01, CYAD-02, incorporates the shRNA targeting NKG2D ligands on CAR-T cells to improve its efficacy and is currently under clinical trials in patients with acute myeloid leukemia and myelodysplastic syndrome (13, 96).